Page 236 - Genentech News Today

"Our results add to an emerging body of literature around the role of adjuvant immunotherapy for renal cell carcinoma. With the longest duration of follow-up to date to our knowledge."

NEW YORK and MAINZ, GERMANY, NOVEMBER 16, 2022 - Pfizer Inc.(Nasdaq: BNTX) today announced that the companies have initiated a Phase 1 study to evaluate the safety, tolerability and immunogenicity of a

Investegate announcements from BioNTech SE, Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection

Three-year outcome data from the STOP-JIA study showed that early methotrexate plus a biologic may aid remission and disease inactivity in pediatric polyarticular juvenile idiopathic arthritis.

In May 2022, Roche was one of the first companies to develop a suite of tests to detect the monkeypox virus and aid in the understanding of why and how the disease is spreading. cobas MPXV for use on cobas

Investegate announcements from F. Hoffmann-La Roche Ltd, Roche receives U.S. FDA Emergency Use Authorization for its high-throughput test to detect monkeypox virus

/PRNewswire/ -- DelveInsights TIGIT Inhibitors Competitive Landscape – 2022 report provides comprehensive global coverage of available, marketed, and...

The Business Research Company’s Pharmaceutical Drugs Market 2022 - Opportunities And Strategies – Global Forecast To 2030

Some encouraging progress was made Thursday in the quest for a coronavirus treatment, but a cure or vaccine is still far away.

TIGIT Inhibitors clinical trial pipeline constitutes 18+ key companies continuously working towards developing 20+ TIGIT inhibitors drugs, analyzes DelveInsight LAS VEGAS, Nov. 16, 2022